PaceMate names former Philips, BioTelemetry leader its new chief commercial officer
PaceMate, a Florida-based healthcare technology company focused on remote monitoring and data management for heart patients, has announced that JR Finkelmeier is the company’s new chief commercial officer. His primary responsibility will be overseeing the commercial expansion of PaceMate’s software and clinical service offerings, including everything from sales to marketing initiatives.
Finkelmeier has more than 20 years of experience in the healthcare and medical device industries. He spent many years with heart rhythm specialists BioTelemetry, for example, helping guide them toward an eventual acquisition by Philips for $2.8 billion. He then stayed with Philips once that deal was finalized, running its ECG solutions business.
“PaceMate is a leader in cardiac care with its advanced cardiac data platform and clinical service capabilities,” Finkelmeier said in a prepared statement. “I'm thrilled to join this dedicated team and accelerate our commercial momentum to expand our impact on cardiac patient lives.”
“JR has demonstrated remarkable success in scaling healthcare and medical technology companies,” added PaceMate CEO Tripp Higgins. “His track record, vision, and expertise make him the ideal leader to drive the adoption of PaceMate’s cardiac monitoring platform and spearhead our next phase of growth.”
Finkelmeier’s arrival comes just one month after PaceMate announced that 100,000 ambulatory patients have now had their care managed with the its PaceMateLIVE offering, which uses advanced artificial intelligence algorithms to manage the full patient journey, from device ordering to billing and beyond.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.